Targets › EZH2
9 programs from 9 companies in 34 trials: 20 Phase 1, 12 Phase 2, 2 Phase 3; Oncology; next expected readout Feb 2027.
Catalytic subunit of the PRC2/EED-EZH2 complex, a Polycomb group (PcG) complex that methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. Able to mono-, di- and trimethylate 'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3, respectively. (UniProt, Q15910)
Open in Phaseline: the race on EZH2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Epizyme | Tazemetostat Histone-lysine N-methyltransferase EZH2 inhibitor | EZH2 | Phase 3 | Relapsed/Refractory Follicular Lymphoma; Peripheral Nerve Sheath Tumor; B-Cell Non-Hodgkin Lymphoma; Grade 3b Follicular Lymphoma … | Feb 2027 |
| Evopoint Biosciences | XNW5004 tablets EZH2 inhibitor | EZH2 | Phase 3 | Relapsed/Refractory Peripheral T Cell Lymphoma; Follicular Lymphoma, Grade 1; Metastatic Castrate-Resistant Prostate Cancer | Jul 2027 |
| National Cancer Institute (NCI) | Tazemetostat Hydrobromide Histone-lysine N-methyltransferase EZH2 inhibitor | EZH2 | Phase 2 | Recurrent Endometrial Endometrioid Adenocarcinoma; Clinical Stage IV Cutaneous Melanoma AJCC v8; Extensive Stage Lung Small Cell Carcinoma; Recurrent B-Cell Non-Hodgkin Lymphoma … | Feb 2027 |
| Fudan University | SHR-2554 EZH2 inhibitor | EZH2 | Phase 2 | Relapsed/Refractory Peripheral T Cell Lymphoma | Feb 2027 |
| The First Affiliated Hospital of Zhengzhou University | SHR2554 EZH2 inhibitor | EZH2 | Phase 2 | Advanced Gastric Cancer | Jul 2027 |
| Daiichi Sankyo | Valemetostat Tosylate EZH1/2 dual inhibitor | EZH1, EZH2, KDM1A | Phase 2 | Relapsed/Refractory Peripheral T-Cell Lymphoma; Non-small Cell Lung Cancer; Advanced Solid Tumor; Lymphoma, B-Cell … | Mar 2028 |
| Hanmi Pharmaceutical Company | HM97662 EZH1/2 dual inhibitor | EZH1, EZH2 | Phase 1 | Advanced or Metastatic Solid Tumors | Jan 2028 |
| Lan Coffman | CPI-0209 EZH2 inhibitor | EZH2 | Phase 1 | Recurrent Ovarian Cancer | Jul 2028 |
| Novartis | Tulmimetostat (DZR123, CPI-0209) Dual EZH1/EZH2 inhibitor | EZH1, EZH2 | Phase 1 | Progressive Metastatic Castrate Resistant Prostate Cancer; Advanced Solid Tumor; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Mycosis Fungoides | Nov 2029 |
Follicular Lymphoma (3) Advanced Solid Tumor (2) Relapsed/Refractory Peripheral T Cell Lymphoma (2) Progressive Metastatic Castrate Resistant Prostate Cancer (1) Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (1) Mycosis Fungoides (1) Recurrent Endometrial Endometrioid Adenocarcinoma (1) Clinical Stage IV Cutaneous Melanoma AJCC v8 (1) Extensive Stage Lung Small Cell Carcinoma (1) Recurrent B-Cell Non-Hodgkin Lymphoma (1) Locally Advanced Urothelial Carcinoma (1) Follicular Lymphoma, Grade 1 (1)
small molecule (7), mixed (2)
Novartis (1) National Cancer Institute (NCI) (1) Evopoint Biosciences (1) Lan Coffman (1) Epizyme (1) Daiichi Sankyo (1) Fudan University (1) The First Affiliated Hospital of Zhengzhou University (1) Hanmi Pharmaceutical Company (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.